SOX2 Expression in Early-Stage Breast Cancer
Author Information
Author(s): Claudia Lengerke, Tanja Fehm, Ralf Kurth, Hans Neubauer, Veit Scheble, Friederike Müller, Friederike Schneider, Karen Petersen, Diethelm Wallwiener, Lothar Kanz, Falko Fend, Sven Perner, Petra M. Bareiss, Annette Staebler
Primary Institution: University of Tuebingen
Hypothesis
Does SOX2 expression play a role in breast carcinogenesis and metastatic potential?
Conclusion
SOX2 is expressed in various early-stage postmenopausal breast carcinomas and may promote metastatic potential.
Supporting Evidence
- SOX2 expression was detected in 28% of invasive breast carcinoma samples.
- High SOX2 expression was associated with larger tumor size and positive lymph node status.
- Metastatic lymph nodes showed higher SOX2 expression compared to primary tumors.
Takeaway
This study found that a protein called SOX2 is present in many early breast cancers, and it might help the cancer spread.
Methodology
Immunohistochemistry and FISH were used to analyze SOX2 expression in tumor samples from postmenopausal breast cancer patients.
Potential Biases
Potential selection bias due to the retrospective nature of the study.
Limitations
The study's findings may not be generalizable beyond postmenopausal patients and require further validation in larger cohorts.
Participant Demographics
Patients were postmenopausal women aged 50 to 69 years.
Statistical Information
P-Value
0.018
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website